MDT-AP-1164
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 12.96
- os_event
- true
- age_years
- 2.5
- sex
- F
- new_clusters
- C3
- umap1_2d
- 5.465863265
- umap2_2d
- 3.28540625
- umap1_3d
- 2.222258664
- umap2_3d
- -2.374580538
- umap3_3d
- -2.111989563
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.480
- INTERFERON_GAMMA_RESPONSE+0.440
- ALLOGRAFT_REJECTION+0.380
- IL6_JAK_STAT3_SIGNALING+0.350
- P53_PATHWAY+0.230
- IL2_STAT5_SIGNALING+0.220
- PANCREAS_BETA_CELLS+0.170
- ANGIOGENESIS+0.160
- INFLAMMATORY_RESPONSE+0.160
- BILE_ACID_METABOLISM+0.150
Top 10 suppressed
- E2F_TARGETS-0.540
- G2M_CHECKPOINT-0.540
- MYC_TARGETS_V1-0.500
- MITOTIC_SPINDLE-0.340
- MYC_TARGETS_V2-0.340
- UNFOLDED_PROTEIN_RESPONSE-0.290
- ANDROGEN_RESPONSE-0.280
- MTORC1_SIGNALING-0.280
- OXIDATIVE_PHOSPHORYLATION-0.230
- UV_RESPONSE_DN-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG7 | — | — | 0.880 |
| 2 | TCGA-85-A513-01A-12R-A26W-07 | — | cohortA1 | 0.854 |
| 3 | C3L-02560 | — | cohortA1 | 0.853 |
| 4 | SJEPD017_D.RNA-Seq | EPN | Supratentorial EPN | 0.847 |
| 5 | TCGA-E9-A5FK-01A-11R-A27Q-07 | — | B | 0.844 |
| 6 | TCGA-XF-A9SK-01A-11R-A42T-07 | — | — | 0.843 |
| 7 | TCGA-A2-A0CR-01A-11R-A22K-07 | — | B | 0.839 |
| 8 | SRR1797234 | — | cohortMD2 | 0.838 |
| 9 | TCGA-38-A44F-01A-11R-A24H-07 | — | cohortA1 | 0.836 |
| 10 | TCGA-L9-A444-01A-21R-A24H-07 | — | cohortA1 | 0.835 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.480 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.380 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.230 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.160 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.160 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.130 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| COAGULATION | 0.120 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.120 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.110 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.110 | Inavolisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |
| COMPLEMENT | 0.060 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |